Boundless Bio Inc. (BOLD) AI Stock Analysis

• Market Cap: $25.97M
• Dividend Yield: N/A
• Average Volume (3M): 219.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.92
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 64
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.71
• Shares Outstanding: 22,385,610
• 10 Day Avg. Volume: 105,238
• 30 Day Avg. Volume: 219,627
• PEG Ratio: 0.64
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: 2.36
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.15
• 1Y Price Target: $4.00
• Price Target Upside: 244.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 40 Underperform
• Price Target: ―

Boundless Bio Inc. scores low due to its challenging financial situation with no revenue and high operational costs, despite some improvements in equity and liquidity. The technical analysis suggests possible short-term recovery potential, but the negative valuation metrics underscore the speculative nature of the stock. Investors should be cautious, as future gains depend heavily on successful product commercialization.

Positive Factors

Clinical Trials

All programs remain on track, with the key proof-of-concept clinical dataset for BBI-355 (CHK1) expected in the second half of 2025.

Financial Stability

The company reported $138 million in cash and cash equivalents, which they expect to provide runway into 2027.

Future Developments

The company continues to expect the nomination of a candidate for the novel kinesin program in mid-2025 and the IND submission for the candidate in the first half of 2026.

Negative Factors

Clinical Trials Setback

The shift in development results in a major setback for BOLD's lead program, as the agent returns to proof-of-principle and dose-optimization efforts and novel combination strategies to improve the therapeutic index.

Diagnostic Delays

The validation of the ecDNA hypothesis with the ECHO diagnostic tool has also been delayed, suggesting the investment thesis may remain in limbo until a new asset, such as the BBI-940, is developed.

Therapeutic Challenges

Combinations of BBI-355 with erlotinib (EGFR) and futibatinib (FGFR) were also not well-tolerated at the Q2D doses required for anti-tumor activity.

Boundless Bio Inc. Business Overview & Revenue Model

Company Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

How the Company Makes Money

Boundless Bio Inc. generates revenue primarily through the development and commercialization of its proprietary therapies targeting ecDNA in cancer cells. The company may receive funding through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, which provide financial support for its research and development activities. Additionally, revenue could be derived from milestone payments and royalties related to the successful advancement and commercialization of its therapeutic products. Public and private funding rounds may also contribute to its financial resources, enabling ongoing research and clinical trials.

Boundless Bio Inc. Financial Statement Overview

Summary

Boundless Bio Inc. is facing significant financial challenges typical of a biotechnology start-up, with no revenue and high operational costs leading to continued losses. While there are improvements in equity and liquidity, the company heavily relies on external financing for operations. Future stability depends on successful product commercialization and operational efficiency improvements.

Income Statement

Boundless Bio Inc. has consistently reported zero revenue over the past years, indicating no sales or commercialized products. The net income has been negative, showing persistent losses, with net losses increasing year-over-year. The negative EBIT and EBITDA margins further highlight operational challenges and high costs relative to non-existent revenues.

Balance Sheet

The company has shown improvement in its equity position, moving from negative equity to a positive equity situation, which indicates better financial stability. However, the debt-to-equity ratio improvement is due to increasing equity rather than reducing liabilities. The company's cash and short-term investments have increased, providing liquidity, but liabilities remain substantial.

Cash Flow

Operating cash flow remains negative, reflecting the company's inability to generate cash from its core operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. However, significant financing activities suggest reliance on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-957.00K	-942.00K	-682.00K	0.00
EBITDA	-64.28M	-48.48M	-45.53M	-24.62M	-121.36M
Net Income	-65.36M	-49.43M	-45.90M	-25.21M	-128.82M
Balance Sheet
Total Assets	206.41M	129.89M	76.83M	113.72M	472.56M
Cash, Cash Equivalents and Short-Term Investments	152.11M	120.75M	66.72M	73.03M	414.31M
Total Debt	47.63M	2.19M	5.18M	377.00K	7.07M
Total Liabilities	55.77M	256.98M	158.53M	151.91M	29.80M
Stockholders Equity	150.64M	-127.08M	-81.70M	-38.19M	442.75M
Cash Flow
Free Cash Flow	-63.38M	-47.49M	-40.66M	-25.28M	-119.59M
Operating Cash Flow	-60.84M	-46.85M	-39.60M	-23.25M	-107.98M
Investing Cash Flow	-26.10M	-38.26M	16.13M	-59.28M	-185.05M
Financing Cash Flow	89.82M	97.90M	126.00K	105.53M	398.46M

Boundless Bio Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLD, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.16, and below the 200-day MA of 1.96, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 47.66 is Neutral, neither overbought nor oversold. The STOCH value of 18.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLD.

Boundless Bio Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	56 Neutral	$6.50B	15.33	-28.41%	6.35%	11.10%	-32.94%
BRNS	56 Neutral	$56.48M	―	-45.40%	―	4413.19%	10.56%
ALGS	51 Neutral	$45.62M	―	-60.44%	―	-76.29%	―
PLUR	49 Neutral	$41.43M	―	-1205.58%	―	203.23%	13.57%
CLGN	45 Neutral	$29.13M	―	-75.27%	―	-76.73%	-85.83%
BOLD	40 Underperform	$25.97M	―	-54.06%	―	―	―
ALXO	39 Underperform	$30.33M	―	-102.99%	―	―	30.37%

Boundless Bio Inc. Corporate Events

Boundless Bio Shifts Focus and Restructures Leadership Team

Boundless Bio announced significant updates to its ecDNA-directed therapy programs and leadership team. The company has decided not to advance its BBI-825 program due to complex treatment landscapes and is focusing resources on BBI-355, with initial clinical data expected in 2025, and the third ecDTx program, aiming for a development candidate by mid-2025. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo stepping in as interim CMO. These strategic decisions extend the company’s operational funding into 2027, demonstrating a commitment to advancing its therapeutic pipeline and addressing unmet oncogene-amplified cancer needs.